{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T16:41:55Z","timestamp":1791909715693,"version":"4.3.4"},"reference-count":68,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2019,11,1]],"date-time":"2019-11-01T00:00:00Z","timestamp":1572566400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,11,1]],"date-time":"2019-11-01T00:00:00Z","timestamp":1572566400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,12,1]],"date-time":"2020-12-01T00:00:00Z","timestamp":1606780800000},"content-version":"am","delay-in-days":396,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.fr","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["La Presse M\u00e9dicale"],"published-print":{"date-parts":[[2019,11]]},"DOI":"10.1016\/j.lpm.2019.08.024","type":"journal-article","created":{"date-parts":[[2019,11,20]],"date-time":"2019-11-20T09:10:54Z","timestamp":1574241054000},"page":"319-327","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"special_numbering":"P2","title":["Therapeutic plasma exchange in thrombotic thrombocytopenic purpura"],"prefix":"10.1016","volume":"48","author":[{"given":"Adrien","family":"Picod","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fran\u00e7ois","family":"Prov\u00f4t","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Coppo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"21","key":"10.1016\/j.lpm.2019.08.024_bib0345","doi-asserted-by":"crossref","first-page":"2836","DOI":"10.1182\/blood-2016-10-709857","article-title":"Thrombotic thrombocytopenic purpura","volume":"129","author":"Joly","year":"2017","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.lpm.2019.08.024_bib0350","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1001\/archinte.1925.00120130092009","article-title":"An acute febrile pleiochromic anemia with hyaline thrombosis of the terminal arterioles and capillaries: an undescribed disease","volume":"36","author":"Moschcowitz","year":"1925","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.lpm.2019.08.024_bib0355","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.7326\/0003-4819-51-6-1409","article-title":"Unusual remission in a case of thrombotic thrombocytopenic purpura syndrome following fresh blood exchange transfusions","volume":"51","author":"Rubinstein","year":"1959","journal-title":"Ann Intern Med"},{"issue":"3","key":"10.1016\/j.lpm.2019.08.024_bib0360","first-page":"219","article-title":"Exchange transfusions in the treatment of thrombotic thrombocytopenic purpura","volume":"13","author":"Bukowski","year":"1976","journal-title":"Semin Hematol"},{"issue":"25","key":"10.1016\/j.lpm.2019.08.024_bib0365","doi-asserted-by":"crossref","first-page":"1386","DOI":"10.1056\/NEJM197712222972507","article-title":"Treatment of thrombotic thrombocytopenic purpura with plasma","volume":"297","author":"Byrnes","year":"1977","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.lpm.2019.08.024_bib0370","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1182\/blood.V54.4.842.842","article-title":"Thrombotic thrombocytopenic purpura and dose of plasma exchange","volume":"54","author":"Taft","year":"1979","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.lpm.2019.08.024_bib0375","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1056\/NEJM199108083250604","article-title":"Comparison of plasma exchange with plasma infusion in the treatment of thrombotic thrombocytopenic purpura","volume":"325","author":"Rock","year":"1991","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.lpm.2019.08.024_bib0380","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1182\/blood.V53.2.333.333","article-title":"Presence of a platelet aggregating factor in the plasma of patients with thrombotic thrombocytopenic purpura (TTP) and its inhibition by normal plasma","volume":"53","author":"Lian","year":"1979","journal-title":"Blood"},{"issue":"23","key":"10.1016\/j.lpm.2019.08.024_bib0385","doi-asserted-by":"crossref","first-page":"1432","DOI":"10.1056\/NEJM198212023072306","article-title":"Unusually large plasma factor VIII: von Willebrand factor multimers in chronic relapsing thrombotic thrombocytopenic purpura","volume":"307","author":"Moake","year":"1982","journal-title":"N Engl J Med"},{"issue":"10","key":"10.1016\/j.lpm.2019.08.024_bib0390","doi-asserted-by":"crossref","first-page":"4235","DOI":"10.1182\/blood.V87.10.4235.bloodjournal87104235","article-title":"Physiologic cleavage of von Willebrand factor by a plasma protease is dependent on its conformation and requires calcium ion","volume":"87","author":"Tsai","year":"1996","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.lpm.2019.08.024_bib0395","doi-asserted-by":"crossref","first-page":"4223","DOI":"10.1182\/blood.V87.10.4223.bloodjournal87104223","article-title":"Partial purification and characterization of a protease from human plasma cleaving von Willebrand factor to fragments produced by in vivo proteolysis","volume":"87","author":"Furlan","year":"1996","journal-title":"Blood"},{"issue":"22","key":"10.1016\/j.lpm.2019.08.024_bib0400","doi-asserted-by":"crossref","first-page":"1585","DOI":"10.1056\/NEJM199811263392203","article-title":"Antibodies to von Willebrand factor\u2013cleaving protease in acute thrombotic thrombocytopenic purpura","volume":"339","author":"Tsai","year":"1998","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.lpm.2019.08.024_bib0405","doi-asserted-by":"crossref","first-page":"1262","DOI":"10.1182\/blood-2004-11-4490","article-title":"ADAMTS13 autoantibodies in patients with thrombotic microangiopathies and other immunomediated diseases","volume":"106","author":"Rieger","year":"2005","journal-title":"Blood"},{"issue":"6855","key":"10.1016\/j.lpm.2019.08.024_bib0410","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1038\/35097008","article-title":"Mutations in a member of the ADAMTS gene family cause thrombotic thrombocytopenic purpura","volume":"413","author":"Levy","year":"2001","journal-title":"Nature"},{"issue":"3","key":"10.1016\/j.lpm.2019.08.024_bib0415","first-page":"149","article-title":"Guidelines on the use of therapeutic apheresis in clinical practice-evidence-based approach from the Writing Committee of the American Society for Apheresis: the seventh special issue: therapeutic apheresis-guidelines 2016","volume":"31","author":"Schwartz","year":"2016","journal-title":"J Clin Apheresis"},{"issue":"2","key":"10.1016\/j.lpm.2019.08.024_bib0420","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1111\/jth.13571","article-title":"Consensus on the standardization of terminology in thrombotic thrombocytopenic purpura and related thrombotic microangiopathies","volume":"15","author":"Scully","year":"2017","journal-title":"J Thromb Haemost"},{"issue":"6","key":"10.1016\/j.lpm.2019.08.024_bib0425","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1007\/BF01696619","article-title":"Thrombotic thrombocytopenic purpura\/hemolytic uremic syndrome: a multivariate analysis of factors predicting the response to plasma exchange","volume":"70","author":"Pereira","year":"1995","journal-title":"Ann Hematol"},{"issue":"2","key":"10.1016\/j.lpm.2019.08.024_bib0430","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1111\/j.1365-2141.1994.tb04915.x","article-title":"The treatment of thrombotic thrombocytopenic purpura: plasma infusion or exchange?","volume":"87","author":"Novitzky","year":"1994","journal-title":"Br J Haematol"},{"issue":"1","key":"10.1016\/j.lpm.2019.08.024_bib0435","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1097\/00005792-200301000-00003","article-title":"High-dose plasma infusion versus plasma exchange as early treatment of thrombotic thrombocytopenic purpura\/hemolytic-uremic syndrome","volume":"82","author":"Coppo","year":"2003","journal-title":"Medicine (Baltimore)"},{"issue":"6","key":"10.1016\/j.lpm.2019.08.024_bib0440","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1007\/s00134-018-5243-4","article-title":"Does this patient with thrombotic thrombocytopenic purpura have a cardiac involvement?","volume":"44","author":"Zafrani","year":"2018","journal-title":"Intensive Care Med"},{"issue":"6","key":"10.1016\/j.lpm.2019.08.024_bib0445","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1002\/jca.21529","article-title":"Plasma exchange in the intensive care unit: technical aspects and complications","volume":"32","author":"Lemaire","year":"2017","journal-title":"J Clin Apheresis"},{"issue":"1","key":"10.1016\/j.lpm.2019.08.024_bib0450","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1046\/j.1538-7836.2003.00004.x","article-title":"Immunoadsorption for the treatment of a patient with severe thrombotic thrombocytopenic purpura resistant to plasma exchange: kinetics of an inhibitor of ADAMTS13: letters to the editors","volume":"1","author":"Kn\u00f6bl","year":"2003","journal-title":"J Thromb Haemost"},{"issue":"6","key":"10.1016\/j.lpm.2019.08.024_bib0455","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1002\/jca.21288","article-title":"The use of 50% albumin\/plasma replacement fluid in therapeutic plasma exchange for thrombotic thrombocytopenic purpura: fifty percent albumin\/plasma fluid for TPE in TTP","volume":"28","author":"O\u2019Brien","year":"2013","journal-title":"J Clin Apheresis"},{"issue":"7","key":"10.1016\/j.lpm.2019.08.024_bib0460","doi-asserted-by":"crossref","first-page":"1798","DOI":"10.1111\/trf.13041","article-title":"Platelet transfusion and catheter insertion for plasma exchange in patients with thrombotic thrombocytopenic purpura and a low platelet count: PLT transfusion for catheter insertion in TTP","volume":"55","author":"Riviere","year":"2015","journal-title":"Transfusion (Paris)"},{"issue":"3","key":"10.1016\/j.lpm.2019.08.024_bib0465","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1002\/ajh.1179","article-title":"Effectiveness of platelet transfusions after plasma exchange in adult thrombotic thrombocytopenic purpura: a report of two cases","volume":"68","author":"Coppo","year":"2001","journal-title":"Am J Hematol"},{"issue":"12","key":"10.1016\/j.lpm.2019.08.024_bib0470","doi-asserted-by":"crossref","first-page":"2525","DOI":"10.1111\/j.1537-2995.2012.03646.x","article-title":"Decreasing frequency of plasma exchange complications in patients treated for thrombotic thrombocytopenic purpura-hemolytic uremic syndrome, 1996 to 2011 (CME): plasma exchange complications in TTP","volume":"52","author":"Som","year":"2012","journal-title":"Transfusion (Paris)"},{"issue":"4","key":"10.1016\/j.lpm.2019.08.024_bib0475","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1111\/j.1423-0410.2011.01562.x","article-title":"Evaluation of the hemostatic potential including thrombin generation of three different therapeutic pathogen-reduced plasmas: hemostatic potential of therapeutic plasma","volume":"102","author":"Hacquard","year":"2012","journal-title":"Vox Sang"},{"issue":"10","key":"10.1016\/j.lpm.2019.08.024_bib0480","doi-asserted-by":"crossref","first-page":"2445","DOI":"10.1111\/trf.13229","article-title":"Type of plasma preparation used for plasma exchange and clinical outcome of adult patients with acquired idiopathic thrombotic thrombocytopenic purpura: a French retrospective multicenter cohort study: therapeutic plasma and TTP outcome","volume":"55","author":"Toussaint-Hacquard","year":"2015","journal-title":"Transfusion (Paris)"},{"issue":"1","key":"10.1016\/j.lpm.2019.08.024_bib0485","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.tracli.2017.10.002","article-title":"Amotosalen-inactivated plasma is as equally well tolerated as quarantine plasma in patients undergoing large volume therapeutic plasma exchange","volume":"25","author":"Guignier","year":"2018","journal-title":"Transfus Clin Biol"},{"issue":"10","key":"10.1016\/j.lpm.2019.08.024_bib0490","doi-asserted-by":"crossref","first-page":"1693","DOI":"10.1111\/j.1537-2995.2006.00959.x","article-title":"A randomized, controlled Phase III trial of therapeutic plasma exchange with fresh-frozen plasma (FFP) prepared with amotosalen and ultraviolet A light compared to untreated FFP in thrombotic thrombocytopenic purpura","volume":"46","author":"Mintz","year":"2006","journal-title":"Transfusion (Paris)"},{"issue":"5","key":"10.1016\/j.lpm.2019.08.024_bib0495","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1111\/vox.12663","article-title":"Characterization of efficacy and safety of pathogen inactivated and quarantine plasma in routine use for treatment of acquired immune thrombotic thrombocytopenic purpura","volume":"113","author":"Herbrecht","year":"2018","journal-title":"Vox Sang"},{"issue":"3","key":"10.1016\/j.lpm.2019.08.024_bib0500","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1046\/j.1365-2141.2001.02991.x","article-title":"Role of methylene blue-treated or fresh-frozen plasma in the response to plasma exchange in patients with thrombotic thrombocytopenic purpura","volume":"114","author":"de la Rubia","year":"2001","journal-title":"Br J Haematol"},{"issue":"4","key":"10.1016\/j.lpm.2019.08.024_bib0505","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1111\/j.0042-9007.2004.00506.x","article-title":"Methylene blue-photoinactivated plasma vs. fresh-frozen plasma as replacement fluid for plasma exchange in thrombotic thrombocytopenic purpura","volume":"86","author":"Alvarez-Larran","year":"2004","journal-title":"Vox Sang"},{"issue":"1","key":"10.1016\/j.lpm.2019.08.024_bib0510","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1111\/j.1365-2141.2008.07292.x","article-title":"Methylene blue-photoinactivated plasma versus quarantine fresh frozen plasma in thrombotic thrombocytopenic purpura: a multicentric, prospective cohort study","volume":"143","author":"del R\u00edo-Garma","year":"2008","journal-title":"Br J Haematol"},{"issue":"1","key":"10.1016\/j.lpm.2019.08.024_bib0515","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1111\/j.1365-2141.2005.05418.x","article-title":"Does cryosupernatant plasma improve outcome in thrombotic thrombocytopenic purpura? No answer yet","volume":"129","author":"Rock","year":"2005","journal-title":"Br J Haematol"},{"issue":"5","key":"10.1016\/j.lpm.2019.08.024_bib0520","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1046\/j.1526-0968.2000.004005327.x","article-title":"Design of the prospective randomized study for the treatment of patients with thrombotic microangiopathy. PRODROMI Study Group","volume":"4","author":"R\u00f6thele","year":"2000","journal-title":"Ther Apher"},{"issue":"1","key":"10.1016\/j.lpm.2019.08.024_bib0525","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1002\/jca.1003","article-title":"Cryoprecipitate poor plasma does not improve early response in primary adult thrombotic thrombocytopenic purpura (TTP)","volume":"16","author":"Zeigler","year":"2001","journal-title":"J Clin Apheresis"},{"issue":"23","key":"10.1016\/j.lpm.2019.08.024_bib0530","doi-asserted-by":"crossref","first-page":"2075","DOI":"10.1182\/bloodadvances.2017009308","article-title":"Cyclosporine or steroids as an adjunct to plasma exchange in the treatment of immune-mediated thrombotic thrombocytopenic purpura","volume":"1","author":"Cataland","year":"2017","journal-title":"Blood Adv"},{"issue":"6","key":"10.1016\/j.lpm.2019.08.024_bib0535","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1007\/s00277-009-0877-5","article-title":"High versus standard dose methylprednisolone in the acute phase of idiopathic thrombotic thrombocytopenic purpura: a randomized study","volume":"89","author":"The Italian TTP Study Group","year":"2010","journal-title":"Ann Hematol"},{"issue":"5","key":"10.1016\/j.lpm.2019.08.024_bib0540","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1002\/jca.20172","article-title":"Rituximab as an adjunct to plasma exchange in TTP: a report of 12 cases and review of literature","volume":"23","author":"Jasti","year":"2008","journal-title":"J Clin Apheresis"},{"issue":"7","key":"10.1016\/j.lpm.2019.08.024_bib0545","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1002\/ajh.21439","article-title":"Sustained response with rituximab in patients with thrombotic thrombocytopenic purpura: a report of 13 cases and review of the literature","volume":"84","author":"Ling","year":"2009","journal-title":"Am J Hematol"},{"issue":"3","key":"10.1016\/j.lpm.2019.08.024_bib0550","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1016\/j.transci.2010.09.018","article-title":"Efficacy and safety of rituximab in adult patients with idiopathic relapsing or refractory thrombotic thrombocytopenic purpura: results of a Spanish multicenter study","volume":"43","author":"de la Rubia","year":"2010","journal-title":"Transfus Apher Sci"},{"issue":"24","key":"10.1016\/j.lpm.2019.08.024_bib0555","doi-asserted-by":"crossref","first-page":"3092","DOI":"10.1182\/blood-2016-03-703827","article-title":"Rituximab reduces risk for relapse in patients with thrombotic thrombocytopenic purpura","volume":"127","author":"Page","year":"2016","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.lpm.2019.08.024_bib0560","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1111\/j.1365-2141.2006.06448.x","article-title":"Remission in acute refractory and relapsing thrombotic thrombocytopenic purpura following rituximab is associated with a reduction in IgG antibodies to ADAMTS-13","volume":"136","author":"Scully","year":"2007","journal-title":"Br J Haematol"},{"issue":"1","key":"10.1016\/j.lpm.2019.08.024_bib0565","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1097\/CCM.0b013e31822e9d66","article-title":"Efficacy and safety of first-line rituximab in severe, acquired thrombotic thrombocytopenic purpura with a suboptimal response to plasma exchange. Experience of the French Thrombotic Microangiopathies Reference Center","volume":"40","author":"Froissart","year":"2012","journal-title":"Crit Care Med"},{"issue":"6","key":"10.1016\/j.lpm.2019.08.024_bib0570","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1111\/j.1538-7836.2010.03818.x","article-title":"Rituximab pharmacokinetics during the management of acute idiopathic thrombotic thrombocytopenic purpura: PK of rituximab in TTP","volume":"8","author":"Mcdonald","year":"2010","journal-title":"J Thromb Haemost"},{"issue":"7","key":"10.1016\/j.lpm.2019.08.024_bib0575","first-page":"1746","volume":"118","author":"Scully","year":"2011","journal-title":"A phase 2 study of the safety and efficacy of rituximab with plasma exchange in acute acquired thrombotic thrombocytopenic purpura. Blood"},{"issue":"2","key":"10.1016\/j.lpm.2019.08.024_bib0580","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1182\/blood-2014-01-550244","article-title":"Preemptive rituximab infusions after remission efficiently prevent relapses in acquired thrombotic thrombocytopenic purpura","volume":"124","author":"Hie","year":"2014","journal-title":"Blood"},{"issue":"20","key":"10.1016\/j.lpm.2019.08.024_bib0585","doi-asserted-by":"crossref","first-page":"2143","DOI":"10.1182\/blood-2018-04-840090","article-title":"Preemptive rituximab prevents long-term relapses in immune-mediated thrombotic thrombocytopenic purpura","volume":"132","author":"Jestin","year":"2018","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.lpm.2019.08.024_bib0590","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1111\/ejh.12706","article-title":"Twice-daily therapeutical plasma exchange-based salvage therapy in severe autoimmune thrombotic thrombocytopenic purpura: the French TMA Reference Center experience","volume":"97","author":"Soucemarianadin","year":"2016","journal-title":"Eur J Haematol"},{"issue":"2","key":"10.1016\/j.lpm.2019.08.024_bib0595","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1111\/j.1537-2995.2007.01530.x","article-title":"Twice-daily plasma exchange for patients with refractory thrombotic thrombocytopenic purpura: the experience of the Oklahoma Registry, 1989 through 2006","volume":"48","author":"Nguyen","year":"2007","journal-title":"Transfusion (Paris)"},{"issue":"25","key":"10.1016\/j.lpm.2019.08.024_bib0600","doi-asserted-by":"crossref","first-page":"3860","DOI":"10.1182\/blood-2014-11-551580","article-title":"How I treat refractory thrombotic thrombocytopenic purpura","volume":"125","author":"Sayani","year":"2015","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.lpm.2019.08.024_bib0605","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1111\/bjh.13993","article-title":"Bortezomib in the treatment of refractory thrombotic thrombocytopenic purpura","volume":"173","author":"Patriquin","year":"2016","journal-title":"Br J Haematol"},{"issue":"10","key":"10.1016\/j.lpm.2019.08.024_bib0610","doi-asserted-by":"crossref","first-page":"2181","DOI":"10.1111\/j.1537-2995.2009.02232.x","article-title":"Anti-von Willebrand factor aptamer ARC1779 for refractory thrombotic thrombocytopenic purpura","volume":"49","author":"Kn\u00f6bl","year":"2009","journal-title":"Transfusion (Paris)"},{"issue":"4","key":"10.1016\/j.lpm.2019.08.024_bib0615","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1002\/ajh.23106","article-title":"Initial experience from a double-blind, placebo-controlled, clinical outcome study of ARC1779 in patients with thrombotic thrombocytopenic purpura","volume":"87","author":"Cataland","year":"2012","journal-title":"Am J Hematol"},{"issue":"17","key":"10.1016\/j.lpm.2019.08.024_bib0620","doi-asserted-by":"crossref","first-page":"3611","DOI":"10.1182\/blood-2012-04-421248","article-title":"Inhibition of von Willebrand factor-platelet glycoprotein Ib interaction prevents and reverses symptoms of acute acquired thrombotic thrombocytopenic purpura in baboons","volume":"120","author":"Feys","year":"2012","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.lpm.2019.08.024_bib0625","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1056\/NEJMoa1505533","article-title":"Caplacizumab for acquired thrombotic thrombocytopenic purpura","volume":"374","author":"Peyvandi","year":"2016","journal-title":"N Engl J Med"},{"issue":"7","key":"10.1016\/j.lpm.2019.08.024_bib0630","doi-asserted-by":"crossref","first-page":"1448","DOI":"10.1111\/jth.13716","article-title":"Caplacizumab reduces the frequency of major thromboembolic events, exacerbations and death in patients with acquired thrombotic thrombocytopenic purpura","volume":"15","author":"Peyvandi","year":"2017","journal-title":"J Thromb Haemost"},{"issue":"4","key":"10.1016\/j.lpm.2019.08.024_bib0635","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1056\/NEJMoa1806311","article-title":"Caplacizumab treatment for acquired thrombotic thrombocytopenic purpura","volume":"380","author":"Scully","year":"2019","journal-title":"N Engl J Med"},{"issue":"25","key":"10.1016\/j.lpm.2019.08.024_bib0640","doi-asserted-by":"crossref","first-page":"6128","DOI":"10.1182\/blood-2011-09-380535","article-title":"A new mouse model mimicking thrombotic thrombocytopenic purpura: correction of symptoms by recombinant human ADAMTS13","volume":"119","author":"Schiviz","year":"2012","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.lpm.2019.08.024_bib0645","first-page":"936","volume":"9","author":"Plaimauer","year":"2011","journal-title":"Recombinant ADAMTS13 normalizes von Willebrand factor-cleaving activity in plasma of acquired TTP patients by overriding inhibitory antibodies: rADAMTS13 overrides inhibitors in TTP plasma. J Thromb Haemost"},{"issue":"16","key":"10.1016\/j.lpm.2019.08.024_bib0650","doi-asserted-by":"crossref","first-page":"3836","DOI":"10.1182\/blood-2011-12-399501","article-title":"Gain-of-function ADAMTS13 variants that are resistant to autoantibodies against ADAMTS13 in patients with acquired thrombotic thrombocytopenic purpura","volume":"119","author":"Jian","year":"2012","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.lpm.2019.08.024_bib0655","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1172\/JCI41062","article-title":"N-acetylcysteine reduces the size and activity of von Willebrand factor in human plasma and mice","volume":"121","author":"Chen","year":"2011","journal-title":"J Clin Invest"},{"issue":"5","key":"10.1016\/j.lpm.2019.08.024_bib0660","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1111\/trf.12440","article-title":"Treatment of refractory thrombotic thrombocytopenic purpura with N-acetylcysteine: a case report: treatment of TTP with N-Acetylcysteine","volume":"54","author":"Li","year":"2014","journal-title":"Transfusion (Paris)"},{"issue":"8","key":"10.1016\/j.lpm.2019.08.024_bib0665","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.1182\/blood-2016-09-738856","article-title":"N-acetylcysteine in preclinical mouse and baboon models of thrombotic thrombocytopenic purpura","volume":"129","author":"Tersteeg","year":"2017","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.lpm.2019.08.024_bib0670","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1002\/rth2.12160","article-title":"Thrombotic thrombocytopenic purpura: toward targeted therapy and precision medicine","volume":"3","author":"Coppo","year":"2019","journal-title":"Res Pract Thromb Haemost"},{"issue":"4","key":"10.1016\/j.lpm.2019.08.024_bib0675","doi-asserted-by":"crossref","first-page":"e10208","DOI":"10.1371\/journal.pone.0010208","article-title":"Predictive features of severe acquired ADAMTS13 deficiency in idiopathic thrombotic microangiopathies: the French TMA Reference Center Experience. Morty RE, editor","volume":"5","author":"Coppo","year":"2010","journal-title":"PLoS ONE"},{"issue":"4","key":"10.1016\/j.lpm.2019.08.024_bib0680","doi-asserted-by":"crossref","first-page":"e157","DOI":"10.1016\/S2352-3026(17)30026-1","article-title":"Derivation and external validation of the PLASMIC score for rapid assessment of adults with thrombotic microangiopathies: a cohort study","volume":"4","author":"Bendapudi","year":"2017","journal-title":"Lancet Haematol"}],"container-title":["La Presse M\u00e9dicale"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0755498219304713?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0755498219304713?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T14:06:31Z","timestamp":1760105191000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0755498219304713"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,11]]},"references-count":68,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2019,11]]}},"alternative-id":["S0755498219304713"],"URL":"https:\/\/doi.org\/10.1016\/j.lpm.2019.08.024","relation":{},"ISSN":["0755-4982"],"issn-type":[{"value":"0755-4982","type":"print"}],"subject":[],"published":{"date-parts":[[2019,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Therapeutic plasma exchange in thrombotic thrombocytopenic purpura","name":"articletitle","label":"Article Title"},{"value":"La Presse M\u00e9dicale","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.lpm.2019.08.024","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}]}}